Factors associated with immunotherapy selection in patients with advanced melanoma

Richard W Joseph, Alicia C. Shillington, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Frank Xiaoqing Liu

Research output: Contribution to journalArticle

Abstract

AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.  Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR]: 6.6; 95% CI: 3.0-14.7), if they were PD-L1 positive (OR: 4.5; 95% CI: 1.9-10.4) or had BRAF wild-type tumor (OR: 2.2; 95% CI: 1.4-3.6). CONCLUSION: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.

Original languageEnglish (US)
Pages (from-to)1361-1369
Number of pages9
JournalImmunotherapy
Volume10
Issue number16
DOIs
StatePublished - Nov 1 2018

Fingerprint

Immunotherapy
Patient Selection
Melanoma
Odds Ratio
Logistic Models
Regression Analysis
Therapeutics
ipilimumab
nivolumab
pembrolizumab
Neoplasms

Keywords

  • advanced melanoma
  • immunotherapy
  • ipilimumab
  • nivolumab
  • pembrolizumab
  • real-world study
  • treatment selection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Joseph, R. W., Shillington, A. C., Macahilig, C., Diede, S. J., Dave, V., Harshaw, Q., & Liu, F. X. (2018). Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 10(16), 1361-1369. https://doi.org/10.2217/imt-2018-0150

Factors associated with immunotherapy selection in patients with advanced melanoma. / Joseph, Richard W; Shillington, Alicia C.; Macahilig, Cynthia; Diede, Scott J.; Dave, Vaidehi; Harshaw, Qing; Liu, Frank Xiaoqing.

In: Immunotherapy, Vol. 10, No. 16, 01.11.2018, p. 1361-1369.

Research output: Contribution to journalArticle

Joseph, RW, Shillington, AC, Macahilig, C, Diede, SJ, Dave, V, Harshaw, Q & Liu, FX 2018, 'Factors associated with immunotherapy selection in patients with advanced melanoma', Immunotherapy, vol. 10, no. 16, pp. 1361-1369. https://doi.org/10.2217/imt-2018-0150
Joseph RW, Shillington AC, Macahilig C, Diede SJ, Dave V, Harshaw Q et al. Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy. 2018 Nov 1;10(16):1361-1369. https://doi.org/10.2217/imt-2018-0150
Joseph, Richard W ; Shillington, Alicia C. ; Macahilig, Cynthia ; Diede, Scott J. ; Dave, Vaidehi ; Harshaw, Qing ; Liu, Frank Xiaoqing. / Factors associated with immunotherapy selection in patients with advanced melanoma. In: Immunotherapy. 2018 ; Vol. 10, No. 16. pp. 1361-1369.
@article{2852cb4fd1d0429a9490972ea39c59bd,
title = "Factors associated with immunotherapy selection in patients with advanced melanoma",
abstract = "AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.  Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR]: 6.6; 95{\%} CI: 3.0-14.7), if they were PD-L1 positive (OR: 4.5; 95{\%} CI: 1.9-10.4) or had BRAF wild-type tumor (OR: 2.2; 95{\%} CI: 1.4-3.6). CONCLUSION: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.",
keywords = "advanced melanoma, immunotherapy, ipilimumab, nivolumab, pembrolizumab, real-world study, treatment selection",
author = "Joseph, {Richard W} and Shillington, {Alicia C.} and Cynthia Macahilig and Diede, {Scott J.} and Vaidehi Dave and Qing Harshaw and Liu, {Frank Xiaoqing}",
year = "2018",
month = "11",
day = "1",
doi = "10.2217/imt-2018-0150",
language = "English (US)",
volume = "10",
pages = "1361--1369",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - Factors associated with immunotherapy selection in patients with advanced melanoma

AU - Joseph, Richard W

AU - Shillington, Alicia C.

AU - Macahilig, Cynthia

AU - Diede, Scott J.

AU - Dave, Vaidehi

AU - Harshaw, Qing

AU - Liu, Frank Xiaoqing

PY - 2018/11/1

Y1 - 2018/11/1

N2 - AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.  Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR]: 6.6; 95% CI: 3.0-14.7), if they were PD-L1 positive (OR: 4.5; 95% CI: 1.9-10.4) or had BRAF wild-type tumor (OR: 2.2; 95% CI: 1.4-3.6). CONCLUSION: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.

AB - AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.  Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR]: 6.6; 95% CI: 3.0-14.7), if they were PD-L1 positive (OR: 4.5; 95% CI: 1.9-10.4) or had BRAF wild-type tumor (OR: 2.2; 95% CI: 1.4-3.6). CONCLUSION: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.

KW - advanced melanoma

KW - immunotherapy

KW - ipilimumab

KW - nivolumab

KW - pembrolizumab

KW - real-world study

KW - treatment selection

UR - http://www.scopus.com/inward/record.url?scp=85057116214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057116214&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0150

DO - 10.2217/imt-2018-0150

M3 - Article

VL - 10

SP - 1361

EP - 1369

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 16

ER -